Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Novo Nordisk

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 17
Average round size
info
The average size of a deal this fund participated in
$46M
Portfolio companies 15
Rounds per year 0.17
Lead investments 2
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.12
Exits 4
Key employees Soon

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical Device
  • Diabetes
Summary

In 1923 was created Novo Nordisk, which is appeared as Corporate Investor. The main office of represented Corporate Investor is situated in the Bagsvu00e6rd. The company was established in Europe in Denmark.

For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most successful fund investment fields, there are Clinical Trials, Health Care. The fund has exact preference in some founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight TransTech Pharma, Beta Bionics, IO Biotech.

The usual things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2015. The fund is constantly included in less than 2 investment rounds annually. The higher amount of exits for fund were in 2014. This Novo Nordisk works on 9 percentage points more the average amount of lead investments comparing to the other organizations. The real fund results show that this Corporate Investor is 8 percentage points less often commits exit comparing to other companies.

The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Novo Nordisk, startups are often financed by Stafford Capital Partners, Sofinnova Partners, Gimv. The meaningful sponsors for the fund in investment in the same round are Yasuda Enterprise Development, Western Technology Investment, Sofinnova Partners. In the next rounds fund is usually obtained by RTW Investments LLC, OrbiMed, Novo Holdings.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Novo Nordisk:
Typical Co-investors
Novo Nordisk is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Novo Nordisk:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
360by360 Competition Italy, Lombardia, Milano
Agroecology Capital California, Palo Alto, United States
ARM IoT Capital -
Bering Waters Ventures -
Cox Enterprises Atlanta, Georgia, United States
D20 Capital California, San Francisco, United States
Dow Jones New York, New York, United States
Fielmann Ventures Germany, Hamburg, Hamburg
Greenwoods Investment China, Shanghai, Shanghai
HERi Africa -
Hermitage Asset Management -
Juesheng.com China, Dongcheng, Shaanxi
maaiiconnect China, Hong Kong, Kowloon
Makerpad Cardiff, United Kingdom, Wales
PASCO Japan, Tokyo
Slaight Communications Canada, Ontario, Toronto
The Andan Foundation Obwalden, Sarnen, Switzerland
Wells Fargo Foundation Minneapolis, Minnesota, United States
xross Chiyoda, Japan

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

The Sabi

Beauty
Cosmetics
Personal Health
$177K06 Apr 2023 Amsterdam, Noord-Holland, The Netherlands

Amalgam Rx

Biotechnology
CRM
Health Care
Information Technology
Life Science
Medical Device
$17M03 Jan 2023 Wilmington, Delaware, United States

Beta Bionics

Biotechnology
Diabetes
Medical Device
$57M17 Feb 2022 Boston, Massachusetts, United States

Sundew

Agriculture
Aquaculture
Biotechnology
$1M24 Sep 2020 Copenhagen, Hovedstaden, Denmark

Beta Bionics

Biotechnology
Diabetes
Medical Device
$63M10 Jan 2019 Boston, Massachusetts, United States

IO Biotech

Biotechnology
Health Care
Therapeutics
$12M05 Jan 2016 Capital Region of Denmark

Beta Bionics

Biotechnology
Diabetes
Medical Device
$5M31 Dec 2015 Boston, Massachusetts, United States

Affimed

Biotechnology
Health Care
Therapeutics
$23M29 Apr 2010 Heidelberg, Baden-Württemberg, Germany

Biotechnology
Medical
Pharmaceutical
$11M03 Sep 2008 San Francisco, California, United States
News
Glooko Raises $30M Series D Financing

– Glooko, a leading provider of remote patient monitoring and chronic care management solutions including diabetes and obesity, has raised a $30m Series D round of funding.
– The financing was led by Health Catalyst Capital along with participation from existing investors Canaan Partners, Georgian, Novo Nordisk, Insulet and Mayo Clinic.
– Proceeds will be used to accelerate organic growth and strategic initiatives across the company’s broad and growing product line of advanced digital health solutions.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Novo Nordisk?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 17
Average round size 46M
Rounds per year 0.17
Peak activity year 2023
Lead investments 2
Follow on index 0.12
Exits 4
Group Appearance index 0.82

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

The Sabi

Beauty
Cosmetics
Personal Health
$177K06 Apr 2023 Amsterdam, Noord-Holland, The Netherlands

Amalgam Rx

Biotechnology
CRM
Health Care
Information Technology
Life Science
Medical Device
$17M03 Jan 2023 Wilmington, Delaware, United States

Beta Bionics

Biotechnology
Diabetes
Medical Device
$57M17 Feb 2022 Boston, Massachusetts, United States

Sundew

Agriculture
Aquaculture
Biotechnology
$1M24 Sep 2020 Copenhagen, Hovedstaden, Denmark

Beta Bionics

Biotechnology
Diabetes
Medical Device
$63M10 Jan 2019 Boston, Massachusetts, United States

IO Biotech

Biotechnology
Health Care
Therapeutics
$12M05 Jan 2016 Capital Region of Denmark

Beta Bionics

Biotechnology
Diabetes
Medical Device
$5M31 Dec 2015 Boston, Massachusetts, United States

Affimed

Biotechnology
Health Care
Therapeutics
$23M29 Apr 2010 Heidelberg, Baden-Württemberg, Germany

Biotechnology
Medical
Pharmaceutical
$11M03 Sep 2008 San Francisco, California, United States
Crunchbase icon

Content report

The following text will be sent to our editors: